Provider Portal
Contact
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Patients deserve the best

CIRCULOGENE provides best in class molecular and genomic tests for the Comprehensive Genomic Profiling of all solid tumors at all stages along with the novel LungLifeAI Risk Stratification test for Indeterminate Pulmonary Nodules. Circulogene provides the only CGP plasma test that combines the most advanced next-generation sequencing (NGS), Plasma PD-L1, and polymerase chain reaction (PCR) technology to detect and monitor cfDNA and cfRNA within well-characterized, well-documented, actionable cancer-associated genes.

CIRCULOGENE uses an innovative approach that has helped oncologists personalize and monitor treatment plans for over 25,000 cancer patients, with the goal of better outcomes and survival. CIRCULOGENE can complement tissue biopsy as recommended by the International Association for the Study of Lung Cancer (IASLC) for enabling a faster time to treatment, providing the right first-line treatment, and resulting in better patient outcomes.

CIRCULOGENE can complement tissue biopsy as recommended by the International Association for the Study of Lung Cancer (IASLC) for enabling a faster time to treatment, providing the right first-line treatment, and resulting in better patient outcomes.

OncoGenLDx

Including NCCN essential guideline & expert based DNA markers

ImmunoClear

Offering the ONLY plasma cfRNA PD-L1

MSI Complete

Utilizing advanced MSI technology

Hereditary Panels

Understanding a patient’s genetics

Each patient’s cancer is unique, understanding the origins and severity of the cancers aids oncologists to personalize the patient’s treatment plan at the time of diagnosis and throughout their cancer journey.

The CIRCULOGENE Best-in-Class Advantage

CIRCULOGENE begins some tests with a proprietary  enrichment process resulting to increase the yield of cfDNA and preserve fragile cfRNA yields. By eliminating the need for a purification step, CIRCULOGENE overcomes the limitations associated with sample volume requirements.  This process preserves and extracts fragile cfRNA, enabling fusions and plasma PD-L1 to be effectively detected.

Learn More

Combined Methodologies

CIRCULOGENE utilizes both NGS and PCR to provide a comprehensive and extensive marker portfolio resulting in accurate results. Rather than limiting the analytical process by only performing NGS, the addition of PCR enables other actionable markers found in RNA mutations and fusions. By combining NGS and PCR instrumentation, CIRCULOGENE provides the breadth of DNA menu and the accuracy for RNA detection.
Learn More
Plasma PD-L1

Plasma PD-L1

The use of PCR enables CIRCULOGENE to provide the only liquid biopsy method to include plasma PD-L1. CIRCULOGENE’s PD-L1 has also been demonstrated to provide valuable information in non-small cell lung cancer (NSCLC) immunotherapy patients.

Learn more

MSI

MSI

CIRCULOGENE utilizes a MSI protocol which consists of eight markers – four of the gold standard markers, plus four novel markers. It has been hypothesized that these eight markers offer greater sensitivity for MSI detection in cancers where the results are otherwise inconclusive or ambiguous.

Learn more

Actionable Reports

Actionable Reports

Our personalized patient reports, highlight the most significant actionable findings. CIRCULOGENE then provides referenced information on current FDA-approved treatment options proven effective for the tumor DNA mutations and RNA fusions identified.

Learn more

CIRCULOGENE News

Back To Top